Clinical Trial

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Name: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma — clinical trial record (NCT05830500)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2023-04-14.

Trial Details

NCT Number	NCT05830500
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Medullary Thyroid Cancer
Enrollment	360 participants
Start Date	2023-06-19
Primary Completion	2027-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2023-07-25